July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Role of Substance P in Promoting Corneal Neovascularization
Author Affiliations & Notes
  • Lingjia Liu
    Schepens Eye Research Institute/Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
    Medical college of Nankai University, Tianjin, China
  • Takeshi Nakao
    Schepens Eye Research Institute/Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Reza Dana
    Schepens Eye Research Institute/Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Jia Yin
    Schepens Eye Research Institute/Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Lingjia Liu, None; Takeshi Nakao, None; Reza Dana, None; Jia Yin, None
  • Footnotes
    Support  National Eye Institute 5K12EY016335
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 950. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lingjia Liu, Takeshi Nakao, Reza Dana, Jia Yin; Role of Substance P in Promoting Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2019;60(9):950.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Substance P (SP) is a key regulator of inflammation and wound healing, and its effects are mainly mediated via neurokinin receptor 1 (NK1R). The aim of this study is to investigate the role of SP in corneal neovascularizaion (KNV) using vascular endothelial cell culture (MS-1 cell line) in vitro and suture-induced KNV mouse model in vivo.

Methods : Vascular endothelial cells (VEC) were treated with 1μmol SP and then cultured for 24 hours. Cell proliferation using BrdU Incorporation assay and tube formation were assessed. KNV was induced by intra-stromal suture placement in BALB/C mice. Topical application of NK1R antagonist Spantide I (three times a day, daily) was applied after suture placement, PBS served as control. Corneal opacity and neovascularization were monitored. After 14 days, the vascularized area was photographed and quantified by double-blind analysis. Corneal opacity also was assessed by photographs. Corneal hem- and lymph-angiogenesis was assessed using immunostaining with CD31 and LYVE1 antibodies, respectively.

Results : SP significantly increased VEC proliferation (+50%, p<0.001). In tube formation assay, both tube length (5.2-fold increase, p=0.001) and number of tube junctions (3.3-fold increase, p=0.003) were significantly increased in the presence of SP. Compared with control group, Spantide I treatment resulted in a significant decrease in vascularized area (85.4%±8.2 in control vs. 66.4%±16.0 in Spantide Ι, P=0.03). Corneal opacity was comparable between control and Spantide Ι groups.

Conclusions : Our results suggest that exogenous SP promotes the proliferation and tube formation of vascular endothelial cells in vitro, demonstrating its pro-angiogenic property. Moreover, blockade of SP-NK1R signaling with Spantide I significantly reduces corneal neovascularization in vivo.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×